Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia

NCT00271063 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphocytic Leukemia

Interventions

DRUG: Liposomal Annamycin

Sponsor

Callisto Pharmaceuticals